New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
... (lisdexamfetamine dimesylate) CII with the proton
pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg ... study is the first to evaluate the impact of a proton
pump inhibitor on the amphetamine ... millions of Americans. Prilosec OTC and other proton
pump inhibitors reduce the acidity (increase the ...
Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
... of the particle accelerator that will deliver proton
therapy at a number of hospitals beginning with ... bring us to system integration and delivery." proton
therapy, widely regarded as the next evolutionary ... However, the large size and high cost of existing proton
therapy systems have made it difficult for the ...
New Proton Therapy Equipment Enables More Tumors to be Treated
... are delivered at the University of Florida proton
Therapy Institute enables physicians to treat ... commonly used scattering method. Until now the proton
beam was "scattered" and flattened using round ... wide protons could travel into the body.
therapy will now be a possible treatment option ...
AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
... bleeding (PUB).(1) To date, there is no proton
pump inhibitor (PPI)
therapy globally approved ... et al. The cost-effectiveness of high-dose oral proton
pump inhibition after endoscopy in the ... (11) Barkun et al. High-dose intravenous proton
pump inhibition following endoscopic ...
IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
... to optimize the seamless integration of proton
therapy delivery and
information management ... management and information system (OIS),
Therapy module, patient immobilization devices, ... solutions to an
extended market. "The IBA proton
therapy solution is intrinsically open to ...
Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
... patients not taking the drugs.
Diabetes Patients on Clopidogrel and proton
Pump Inhibitors at Greater Risk for Cardiovascular Events
New research ... diabetes who take clopidogrel (the active ingredient in Plavix(R)) and proton
pump inhibitors (PPIs) together. A growing body of evidence highlights ...
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
... - Four of the most commonly used proton
pump inhibitors raise risk of heart attack and stroke for patients taking ... (SCAI).
The study found that using any one of several different proton
pump inhibitors (PPIs) in conjunction with clopidogrel increases the risk ...
American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought
... has mild or no symptoms. It is not known whether treatment of GER with proton
pump inhibitors (PPIs) in poorly-controlled asthmatics without GER ... asymptomatic GER in patients with poorly controlled asthma, treatment with proton
pump inhibitors does not improve control. Silent GER is not a likely cause ...
FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
... NEXIUM was first launched outside the US in
2000 and in the US in 2001. proton
Pump Inhibitors (PPIs) have been shown
to be beneficial for patients with ... in the U.S. in 1989, was the first in a class of
medications called proton
pump inhibitors (PPIs) that block acid production
by inhibiting an enzyme ...
Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
... MRI Breast Spectroscopy
A recent study published in Radiology found that proton
spectroscopy may eliminate 68 percent of biopsies for benign ... L, et al "Enhancing Nonmass Lesions in the Breast: Evaluation with proton
1(H) MR Spectroscopy" Radiology 2007; 245: 80-87. About Siemens Medical ...
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other proton
pump inhibitors, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ...
Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment
... esophagus. Approximately 19 million adults in the U.S. suffer on a daily basis from the symptoms of GERD. Medical therapy, such as the daily use of proton
pump inhibitors (PPIs), may improve heartburn symptoms but it does not address the mechanically defective sphincter, allowing gastric reflux to ...
Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
... is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton
therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical ...
Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis
... vomiting, stomach pain, chest pain, heartburn, loss of weight, and food impaction. Other symptoms may include reflux that does not respond to proton
pump inhibitor therapy, failure to thrive, poor appetite, malnutrition and difficulty sleeping.
The double-blind, randomized, ...
Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
... Center(TM) at Swedish Medical Center, and
Northwest Hospital Gamma Knife Center. SCI is also working toward adding
the latest generation of proton
beam radiotherapy systems to this arsenal
of cancer-fighting tools by December 2010.
TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
... TAP Pharmaceutical Products Inc.
today reported results from three pivotal Phase 3 studies evaluating
investigational new drug TAK-390MR, the first proton
pump inhibitor (PPI)
with an innovative dual delayed release technology, in healing patients
with erosive esophagitis (EE) and in maintenance of ...
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
... coupled with reduced ability to
clear the bolus, appears to precipitate reflux symptoms. Despite adequate
control of intra-gastric acidity with proton
pump inhibitors, a proportion
of GERD patients continues to have residual symptoms. Through improvement
of GI motility and increases in the rate of ...
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study
... surrounded by a 20mg coating of an immediate release
formulation of a proton
The PA 325, 28 day study, involved two groups of 40 ... for proprietary fixed dose combinations of naproxen
with the proton
pump inhibitor esomeprazole magnesium in a single
tablet for conditions ...
Pozen Announces Positive Outcome for PA 325
... fourth quarter of 2006.
PA 325 is a patented formulation of 325mg of aspirin surrounded by
a 20mg coating of an immediate release formulation of a proton
The PA 325, 28 day study, involved two groups of 40 subjects
over the age of 50. Each subject was treated with either once a ...
Eurand Announces Positive Phase III Clinical Study Results
study, the level of fat absorption achieved with Zentase was very
high and close to levels seen in healthy patients, even without the
use of proton
pump inhibitors (PPIs). This high fat absorption,
without relying on PPIs could significantly reduce the number of
pills patients take each day."
Addex Achieves Statistically Significant Outcome in Phase IIa
Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
... for which there is an important unmet medical need."
GERD is estimated to affect 15% of the adult population in the
US. The proton
pump inhibitors (PPIs) are the market leaders, with
annual worldwide sales of approximately $16 billion. Their
mechanism of action in GERD is ...
Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
... including antidepressants, anti-psychotics, anti-arrhythmics, and beta-blockers. The second, CYP2C19, metabolizes anticoagulants, anticonvulsants, proton
pump inhibitors, benzodiazepines, anti-malarials, and other medications. The literature has shown that a genotype screen, such as the AmpliChip CYP ...